To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl2 in the daily clinical practice.
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 / Caffo, O., Frantellizzi, V., Tucci, M., Galli, L., Monari, F., Baldari, S., Masini, C., Bortolus, R., Facchini, G., Alongi, P., Agostini, S., Zichi, C., Biasco, E., Fanti, S., Pignata, S., Filice, A., Borsatti, E., Rossetti, S., Spada, M., Cortesi, E., et al.. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - (2020). [10.1007/s00259-020-04796-w]
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223
Frantellizzi, VivianaSecondo
;Cortesi, Enrico;De Vincentis, GiuseppeUltimo
2020
Abstract
To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl2 in the daily clinical practice.| File | Dimensione | Formato | |
|---|---|---|---|
|
Caffo_Fracture-risk_2020.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
229.04 kB
Formato
Adobe PDF
|
229.04 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
